<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04779840</url>
  </required_header>
  <id_info>
    <org_study_id>WP-2019-06</org_study_id>
    <nct_id>NCT04779840</nct_id>
  </id_info>
  <brief_title>Retrospective Study on the Incidence and Management of Anemia in Oncology</brief_title>
  <acronym>RESPIRE</acronym>
  <official_title>Retrospective Study on the Incidence and Management of Anemia in Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weprom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weprom</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often&#xD;
      present at diagnosis and increases with specific treatments. It has an impact on overall&#xD;
      survival and quality of life. Its origins are multiple (pure iron deficiency or functional,&#xD;
      malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy,&#xD;
      targeted therapies).&#xD;
&#xD;
      Transfusion is the most common treatment offered in the management of anemia. The incidence&#xD;
      of anemia and its consequences are often underestimated during cancer management.&#xD;
&#xD;
      Recommendations were published in 2012. An inventory of the incidence of anemia before and&#xD;
      after the publication of these recommendations are proposed in order to assess their impact&#xD;
      on daily practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Actual">January 20, 2021</completion_date>
  <primary_completion_date type="Actual">January 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of anemia</measure>
    <time_frame>2 years</time_frame>
    <description>number of patient with anemia (&lt;11.0 g/dL) upon admission to hospital on the number of patients hospitalized over the period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of transfusion prescriptions</measure>
    <time_frame>2 years</time_frame>
    <description>number of transfusions performed on the number of patients hospitalized over the period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of erythropoiesis stimulating agents (EPO) prescriptions</measure>
    <time_frame>2 years</time_frame>
    <description>number of prescriptions for erythropoiesis stimulating agents (EPO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of iron prescriptions</measure>
    <time_frame>2 years</time_frame>
    <description>number of prescriptions of iron (oral and intravenous)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time between last transfusion and date of death</measure>
    <time_frame>2 years</time_frame>
    <description>Delay between the date of the last transfusion and the date of patient's death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Delay between the enrollment date and the date of patient's death</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">349</enrollment>
  <condition>Anemia</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>period 2011</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>period 2018</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>anemia assessment</intervention_name>
    <description>evaluation of anemia status</description>
    <arm_group_label>period 2011</arm_group_label>
    <arm_group_label>period 2018</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with cancer and justifying continuous hospitalization for more than one&#xD;
        night regardless of pattern.&#xD;
&#xD;
        Patient informed and not having expressed opposition to the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old,&#xD;
&#xD;
          -  Follow-up for cancer justifying hospitalization,&#xD;
&#xD;
          -  Presenting anemia defined by a hemoglobin level &lt;11 g / dL,&#xD;
&#xD;
          -  Patient not having objected to the collection of his data after oral and written&#xD;
             information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with a hemoglobin level ≥ 11 g / dL,&#xD;
&#xD;
          -  adult patients under guardianship, curatorship or deprived of liberty,&#xD;
&#xD;
          -  pregnancy or breast-feeding in progress at the time of hospitalization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katell LE DÛ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Jean Bernard/Clinique Victor Hugo - LE MANS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Jean Bernard - Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

